26 results about "Psoriasis universalis" patented technology

The invention provides an oral medicine formula for treating psoriasis, and relates to the field of traditional Chinese medicine formulas. The oral medicine for treating psoriasis is prepared from the following raw materials by weight: 10 g of astragalus membranaceus, 50 g of rhizoma smilacis glabrae, 10 g of salvia miltiorrhiza, 10 g of cassia twig, 10 g of cicada slough, 10 g of ligusticum wallichii, 30 g of angelica sinensis and 10 g of honey-fried licorice root. Salvia miltiorrhiza, ligusticum wallichii, angelica sinensis and other medicines have the effects of promoting blood circulation to remove blood stasis, can improve the blood circulation state of skin and promote repair of skin lesions, and have a certain curative effect on blood stasis type psoriasis patients; cassia twig and cicada slough have the effects of dispelling wind and arresting itching, can relieve the symptom of skin itch, and improve the life quality of patients; astragalus membranaceus, angelica sinensis and honey-fried licorice root have the effects of reinforcing qi and nourishing blood, can improve the overall physique of a patient, enhance the immunity of the body and contribute to disease recovery, the clinical effective rate reaches 70% or above, one treatment course lasts for three months, and the cure rate can reach 40% or above.

The present invention relates to a polymer self-assembly nanocarrier and a method of preparing same, the nanocarrier binding a peptide that targets a specific cell and, simultaneously, carrying an active ingredient that has been verified. The present invention can exhibit various effects such as a moisturizing effect, an increase in filaggrin production, whitening, skin barrier reinforcement and the like by selectively and efficiently delivering a drug through a targeting peptide, can be applied to skin diseases such as atopy or psoriasis, and is expected to enable the maximum effect of an active substance in the pharmaceutical and cosmetic fields to be obtained.

The invention discloses a cream for treating erythroderma type psoriasis and a preparation method thereof, and belongs to the technical field of psoriasis drugs, the cream is prepared from the following raw materials by weight: 20-50 parts of cassia alata, 5-15 parts of prepared myrrh, 2-8 parts of raw rehmannia root, 40-160 parts of water, 40-50 parts of an emulsifier, and 0.05-0.1 part of a preservative. The preparation method comprises the following steps: decocting the cassia alata, the prepared myrrh and the radix rehmanniae recen in water, and then fishing out the medicinal materials to obtain medicine slurry; and mixing the medicine slurry, the emulsifier and the preservative, adding into an emulsifying machine, and emulsifying to obtain the product. The formula can be used for treating erythroderma type psoriasis, and the external emulsifiable paste for psoriasis has the effects of inhibiting various fungi and viruses, removing heat to cool blood, astringing and promoting tissue regeneration, inhibiting epidermal cell proliferation, slowing down epidermal metabolism cycle speed, promoting keratinogenesis, inhibiting sebum secretion and inhibiting the growth environment of bacteria and fungi. The inflammation cells are eliminated; the itching is relieved, and the like.

A topical cutaneous composition remarkably reduced eczema, psoriasis, and other skin problems in human patients. The topical cutaneous composition is formulated using natural and toxicologically harmless components as a skin cream with an acidic or a caustic property. When the topical cutaneous composition is applied to the afflisted area, the topical cutaneous composition attacks, sooths, and cures damaged skin.

The present disclosure includes methods of treating a disease or condition that produces skin inflammation and / or itch. More specifically the present disclosure relates to treating skin inflammation and itch caused by diseases or disorders of the skin such as psoriasis by administering a peptide fragment of the MARCKS protein. Peptide fragments and variants thereof as disclosed in the present disclosure are useful in such methods.

Cosmetic care composition for topical application to sensitive and inflamed skin, in particular for the relief of psoriasis symptoms or atopic dermatitis symptoms, comprising in weight percent: Manuka honey with a defined UMF ≥15+ or MGO ≥540 mg / kg in a concentration of at least 4% in combination with Aloe Vera juice concentrate in a concentration of at least 0.1%, Panthenol in a concentration of at least 3.0%, squalane in a concentration of at least 6.0%, Shea butter in a concentration of at least 4.0%, and hyaluronic acid in a concentration of at least 0.02%, at least one natural emulsifier and humectant, and a preservation system, and where the rest is water ad 100%.

The invention relates to the technical field of tissue engineering repair and regeneration, in particular to application of a human dental pulp stem cell-derived exosome in preparation of drugs, and particularly application of the human dental pulp stem cell-derived exosome in preparation of drugs, in particular to application of the human dental pulp stem cell-derived exosome in preparation of drugs for treating scytitis and psoriasis, and application of the human dental pulp stem cell-derived exosome in preparation of drugs for treating scytitis and psoriasis. A safe and effective biological intervention measure is constructed to replace a traditional treatment mode, the excessive inflammatory response of the skin is effectively inhibited, meanwhile, skin injuries are repaired, recovery of a lesion area is promoted, and a new treatment measure is provided for a patient with skin inflammation.

The invention discloses a traditional Chinese medicine preparation for treating intractable skin diseases and a preparation method of the traditional Chinese medicine preparation. The traditional Chinese medicine preparation is prepared from the following raw materials in parts by weight: 10-50 parts of paper mulberry leaves, 10-50 parts of rhizoma smilacis glabrae, 10-30 parts of euphorbia cordifolia, 10-30 parts of trichosanthes kirilowii roots, 10-30 parts of spina gleditsiae and 3-5 parts of liquorice. The traditional Chinese medicine preparation is specially used for treating (conditioning) intractable skin diseases such as eczema, psoriasis (psoriasis), allergic dermatitis, lupus erythematosus and the like, is high in cure rate and small in side effect, and solves the problem that no medicine can treat the intractable skin diseases in the world.

The invention discloses an external compound preparation for treating skin diseases as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation is prepared from the following raw materials in specific parts by weight: borneol, dipterex tablets, cantharides, huechys sanguinea, ephedra, calculus bovis, dragon's blood, centipedes and garter snakes. The preparation method comprises raw material pretreatment, mixing and blending, and sub-packaging and storage, and is simple in process and easy to operate; the ointment is externally applied to skin lesions every morning and evening, and is suitable for diseases such as eczema, psoriasis, neurodermatitis and the like. Through the synergistic effect of multiple components, the comprehensive curative effects of clearing heat, detoxifying, dredging collaterals, relieving itching and promoting tissue regeneration are achieved, the traditional Chinese medicine composition has the advantages of being rapid in effect taking, convenient to externally use and small in side effect, the problems that an existing skin disease treatment medicine is large in side effect and slow in effect taking are solved, and a new effective scheme is provided for clinical treatment of skin diseases.

This invention discloses a traditional Chinese medicine composition for treating skin diseases and its preparation method, belonging to the field of traditional Chinese medicine technology. It is made from the following raw materials in parts by weight: 8-12 parts of Phellodendron bark, 8-12 parts of Cnidium monnieri fruit, 8-12 parts of Dictamnus dasycarpus root bark, 8-12 parts of Stemona japonica root bark, 8-12 parts of alum, 8-12 parts of Carthamus tinctorius flower, 8-12 parts of dragon's blood, 8-12 parts of Panax notoginseng root bark, 8-12 parts of myrrh, 8-12 parts of frankincense, and 1-3 parts of propolis. This invention also provides an external preparation containing this composition and its preparation method. The preparation method includes pulverizing the raw materials, adding 60%-80% ethanol, soaking at 50-80℃ for 2-7 days, pressing, filtering, and allowing to stand, then collecting the supernatant. Pharmacological experiments show that the composition of this invention has significant antibacterial, anti-inflammatory, and antipruritic effects; clinical observations show a total effective rate of 80%-95% for psoriasis, eczema, rashes, pruritus, herpes, urticaria, and insect bite itching. The formulation of this invention is scientific, the process is stable, and the efficacy is definite, making it suitable for clinical application.

Uses are described for hemolymph, contents of hemolymph, fragments or components of the contents found within hemolymph, including hemocyanin, any of which may be derived from crustaceans, as functional agents to treat diseases, provide symptomatic relief, provide a beautifying or relieving effect to the intended organ or site-of-intended-use, or be used as an ingredient in formulations designed to aid in the relief of pathologies or states commonly associated with inflammation and dry skin, including, but not limited to eczema, dermatitis, psoriasis, cystitis, asthma, sinusitis, joint pain, as well as other instances of acute and chronic inflammation, and for relief of general symptoms that may be associated with inflammation and dry skin but not linked directly in the intended use, including, but not limited to, redness, itchiness, irritation, muscle or joint fatigue, swelling, hydrating the skin, and reducing transepidermal water loss (TEWL).

The present invention relates to a composition and use thereof directed towards treating various health ailments, such as skin and respiratory problems and various infections. More particularly, the present invention relates to a lime sulfur solution and use thereof, of varying percentages, directed towards improving vision and treating various skin problems and infections, such as toenail fungus, athlete's foot, jock itch, skin psoriasis, eczema, vaginal yeast infections, head or beard dandruff, respiratory infections, itching of the skin (particularly of the hands), acne (facial and / or body acne), poison ivy, insect bites, head and body lice, crabs, cuts, treating wounds infected by staff and / or MRSA (methicillin-resistant Staphylococcus aureus) bacteria, tongue thrush, ringworm, penis foreskin infections, skin tags, and is also directed towards treating various respiratory infections (such as pneumonia, chronic obstructive pulmonary disease (COPD), asthma, and Covid-19 infections). The present invention also relates to use of the aforementioned composition and solution as a disinfectant in gyms, spas, saunas, for professional athletes, or as a body and / or hair wash.

Microneedle Patch for Biphasic Drug Delivery to Enhance the Management of Psoriasis

The invention relates to the technical field of pharmaceutical preparations, in particular to an antibacterial and anti-inflammatory ointment for treating psoriasis and a preparation method thereof.The antibacterial and anti-inflammatory ointment is prepared from, by mass, 0.3%-0.7% of heparin sodium, 12.3%-13.5% of a humectant, 0.05%-0.1% of a penetration enhancer, 0.3%-0.4% of a pH regulator, 0.3%-0.7% of a thickening agent, 0.1%-0.2% of a preservative, 0.1%-0.2% of essence and the balance solvent. The antibacterial and anti-inflammatory ointment for treating psoriasis prepared by the invention has relatively high transdermal absorbability and a good treatment effect.

There is provided topical pharmaceutical formulations comprising montelukast, or a pharmaceutically acceptable salt of solvate thereof, as well as combination products comprising (a) at least one mussel adhesive protein or a derivative thereof; and (b) montelukast, or a pharmaceutically-acceptable salt or solvate thereof. The formulations and combination products find particular utility in direct topical administration for the treatment of inflammation, of inflammatory disorders and / or of condition characterized by inflammation, including wounds, burns, psoriasis, acne and atopic dermatitis.

The disclosure provides a method of predicting a response to a treatment regimen for psoriasis in a subject. Biomarkers and clinical variables that can be used to predict the response and to select a treatment regimen are described herein. Also described is a kit for predicting a response to a treatment regimen for psoriasis in a subject.

Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of diseases and / or conditions of the skin, including hidradenitis suppurativa, atopic dermatitis, psoriasis, vitiligo, and alopecia areata, as well as other diseases and / or conditions provided herein.

The present invention relates to 8-heterocyclic-3-(phenylsulfonyl)-[1,2,3]triazolo[1,5a]quinazolin-5(4H)-one derivatives and pharmaceutical compositions thereof, as well as their use in methods for reducing the virulence of bacteria (preferably Staphylococcus aureus) expressing accessory gene regulator A (AgrA) or an ortholog of AgrA, their use in methods for inhibiting quorum sensing in bacteria, preferably Staphylococcus aureus, and their use in methods for preventing or treating diseases caused or exacerbated by bacteria, preferably Staphylococcus aureus, such as skin or lung infections, atopic dermatitis, Netherton syndrome, or psoriasis in a subject. The compounds have demonstrated excellent ability to inhibit transcription of genes under the control of the P3 promoter in S. aureus, even in the presence of human serum or human serum albumin.

The present inventors discovered that an HMGB1 fragment peptide having a specific amino acid sequence exhibits an effect of suppressing erythema, scaling (desquamation), and thickening (infiltration) of the skin in an animal model of psoriasis. Based on these findings, pharmaceutical compositions for the prevention and / or treatment of psoriasis, which comprise the HMGB1 fragment peptide having the specific amino acid sequence are provided.

The disclosure provides a method of predicting a response to a treatment regimen for psoriasis in a subject. Biomarkers and clinical variables that can be used to predict the response and to select a treatment regimen are described herein. Also described is a kit for predicting a response to a treatment regimen for psoriasis in a subject.

To provide methods for treating various spondyloarthritic and psoriatic conditions.SOLUTION: Provided are methods for treating various spondyloarthritic and psoriatic conditions, including types of axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis (PsO), by a JAK1 inhibitor, upadacitinib free base or a pharmaceutically acceptable salt thereof. In various aspects, methods for treating active non-radiographic axSpA (nr-axSpA), methods for treating active ankylosing spondylitis (AS), methods for treating active psoriatic arthritis (PsA), and methods for treating active psoriasis (PsO) are provided.SELECTED DRAWING: Figure 1

The present disclosure provides pharmaceutical compositions comprising mometasone and diisopropyl adipate (DIPA) for topical administration. These compositions can be formulated as creams, lotions, and foams, and are particularly suitable for administration in hairy skin; for example, for treating inflammatory skin conditions, such as dermatitis, eczema, and psoriasis.

The application belongs to the technical field of medicine, and discloses skin health antipruritic liquid, which comprises raw material components: angelica, cortex moutan, white alum, forsythia, schizonepeta, baizhi, humulus, zanthoxylum, lotus house, artemisia leaf, duckweed, alkanna, aloe, honeycomb, polygonatum, stemona, sophora, fly Yang grass, cortex periplocae, melaleuca, ophiorrhiza, white milkweed, gallic, spilanthes, kochia, taraxacum, clematis, xuchangqing, biota, radix falcaliae, radix pterostupiae, red plate, snake skin, wind-preventing plant, hollyhock, oak flower, oak, radix scrophulariae, radix paeoniae, radix bupleuri, radix scrophulariae, radix paeoniae, radix scrophulariae, radix paeoniae, radix scrophulariae, borage, borax, the application has multiple effects of clearing heat and cooling blood, sterilizing and resisting inflammation, removing dampness and relieving itching, removing toxicity and resolving mass, etc., can improve or treat various skin problems such as eczema, herpes, allergic dermatitis, tinea pedis, hemorrhoids, acne, psoriasis and skin itching, and is suitable for a wide range of scenes; the process combination of crushing, screening, specific proportion mixing, fermentation, multiple filtration and accurate concentration ensures that the active ingredients in the raw materials are fully extracted and purified, avoids the loss of effective components, improves the curative effect intensity of unit volume of liquid medicine, and has quick effect after spraying, which is beneficial to actual application and operation.

The invention discloses a cream for treating psoriasis vulgaris and a preparation method thereof, and belongs to the technical field of psoriasis drugs, the cream is prepared from the following raw materials by weight: 20-50 parts of coal tar, 2-8 parts of sophora flavescens, 2-8 parts of raw rehmannia root, 40-160 parts of water, 40-50 parts of an emulsifier, and 0.05-0.1 part of a preservative. The preparation method comprises the following steps: decocting the radix sophorae flavescentis and the radix rehmanniae recen in water, and then fishing out the medicinal materials to obtain medicine slurry; and mixing the medicine slurry, coal tar, an emulsifier and a preservative, adding into an emulsifying machine, and emulsifying to obtain the product. The formula can be used for treating psoriasis vulgaris, and the external cream for psoriasis has the effects of killing fungi, inhibiting viruses, removing heat to cool blood, resisting oxidation activity, inhibiting epidermal cell proliferation, slowing down epidermal metabolism cycle speed, promoting keratinogenesis, inhibiting sebum secretion, inhibiting growth environment of bacteria and fungi, eliminating inflammatory cells, relieving itching and the like.

The subject matter disclosed herein is generally directed to methods and compositions for modulating inflammation driven by differentiation of quiescent tissue-resident ILCs into a spectrum of pathogenic effectors. The subject matter disclosed herein is also generally directed to detecting and monitoring an ILC response. Additionally, the subject matter is directed to treating skin inflammation, such as psoriasis.

A skin treatment device includes: an elastic enclosure having a hollow center chamber with an opening at a proximal end thereof; a lip around a perimeter of the opening; protrusions and channels on the lip, which selectively: (i) permit expulsion of air and water from the chamber during initial compression of the device against the skin; (ii) terminate the flow of air and water from the chamber when the lip has been sufficiently compressed against the skin to form a seal between the lip and skin; and (iii) permit air to enter the chamber upon decompression of the device and breaking the seal; and at least one outlet valve on the enclosure configured to permit an additional flow of air and water out of the chamber during compression and to resist admission of air or water into the chamber during decompression. A skin treatment method is also disclosed.